AbbVie cancer drug fails two late-stage trials

AbbVie Inc said on Wednesday that its experimental cancer drug, veliparib, failed to meet the main goals of two late-stage studies.

The trials evaluated the effect of veliparib, in combination with a chemotherapy regimen, on patients with non-small cell lung cancer (NSCLC) and triple-negative breast cancer.

In one trial, the combination treatment failed to improve the overall survival of NSCLC patients, who had smoked within the past 12 months and had more than 100 smoking events in their lifetime.

In another trial, which evaluated the treatment on patients with early-stage triple-negative breast cancer, the drug did not achieve the complete pathologic response.

Veliparib belongs to a closely watched class of new medicines called PARP inhibitors, which block enzymes involved in repairing damaged DNA, thereby helping to kill cancer cells.

The only approved drugs in the class include AstraZeneca Plc’s Lynparza, also known as olaparib, and Tesaro Inc’s niraparib.

Tesaro’s niraparib won the U.S. Food and Drug Administration’s approval for the treatment of recurrent ovarian cancer late in March this year.

Other experimental PARP inhibitors include Clovis Oncology Inc’s rucaparib and Pfizer Inc’s talazoparib.

Abbvie’s shares were marginally down after the bell on Wednesday.

(Reporting by Divya Grover in Bengaluru; Editing by Savio D’Souza and Bill Rigby)

Read More at Reuters

Get more stuff like this
in your inbox

Subscribe to our mailing list and get interesting stuff and updates to your email inbox.

Thank you for subscribing.

Something went wrong.

No Preview
These Are the Best Walking Workouts, According to Fitness Experts
This 5-Move Dumbbell Routine Builds Strength in Every Muscle Group
Running Success Can Be Contagious, Says New Study
Get Ready for Summer With This Full-Body Workout From the Tone It Up Girls
Beauty queen uses platform to bring attention to rare genetic disorder
The Inspiring Way This Fitness Blogger Flips the Script On Negative Self-Talk
School crossing guard, 91, marks 50 years of service
Fearing disease, Kenyans burn animal carcasses as drought deepens
The Salad Trend You Didn’t Know You Needed
Leonardo DiCaprio Invests in Sustainable Seafood Line
Why Bob Harper Is Eating a Mediterranean Diet Post Heart Attack
A Foolproof Way to Grow Your Own Food (Even with a Black Thumb)
No Preview
These Are the Best Walking Workouts, According to Fitness Experts
Injured Venezuela protesters face another woe: finding medicine
U.S. top court grapples over making copycat biologics available sooner
Conservative House group says ready to back latest U.S. healthcare bill